Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (SHE:301096) — Market Cap & Net Worth
Market Cap & Net Worth: Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (301096)
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (SHE:301096) has a market capitalization of $881.33 Million (CN¥6.02 Billion) as of June 18, 2026. Listed on the SHE stock exchange, this China-based company holds position #9632 globally and #2549 in its home market, demonstrating a -4.47% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.'s stock price CN¥55.14 by its total outstanding shares 109228284 (109.23 Million). Review Hangzhou Bio-Sincerity Pharma-Tech Co.Lt balance sheet liabilities to assess the company's total debt and financial obligations.
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. Market Cap History: 2021 to 2026
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.'s market capitalization history from 2021 to 2026. Data shows change from $1.34 Billion to $881.33 Million (-12.13% CAGR).
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.35x
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.'s market cap is 1.35 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $1.34 Billion | $374.31 Million | $111.09 Million | 3.58x | 12.06x |
| 2022 | $1.07 Billion | $607.41 Million | $194.16 Million | 1.77x | 5.53x |
| 2023 | $1.04 Billion | $1.02 Billion | $271.97 Million | 1.02x | 3.81x |
| 2024 | $606.42 Million | $801.92 Million | -$52.74 Million | 0.76x | N/A |
| 2025 | $913.30 Million | $677.99 Million | -$90.40 Million | 1.35x | N/A |
Competitor Companies of 301096 by Market Capitalization
Companies near Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. in the global market cap rankings as of June 18, 2026.
Key companies related to Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #15 globally with a market cap of $936.50 Billion USD.
- Eli Lilly and Company (SA:LILY34): Ranked #17 globally with a market cap of $853.51 Billion USD ( R$4.35 Trillion BRL).
- Johnson & Johnson (NYSE:JNJ): Ranked #26 globally with a market cap of $564.26 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #41 globally with a market cap of $356.49 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #15 | Eli Lilly and Company | NYSE:LLY | $936.50 Billion | $1112.00 |
| #17 | Eli Lilly and Company | SA:LILY34 | $853.51 Billion | R$153.70 |
| #26 | Johnson & Johnson | NYSE:JNJ | $564.26 Billion | $234.20 |
| #41 | AbbVie Inc | NYSE:ABBV | $356.49 Billion | $221.23 |
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. Historical Marketcap From 2021 to 2026
Between 2021 and today, Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.'s market cap moved from $1.34 Billion to $ 881.33 Million, with a yearly change of -12.13%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥881.33 Million | -3.50% |
| 2025 | CN¥913.30 Million | +50.61% |
| 2024 | CN¥606.42 Million | -41.44% |
| 2023 | CN¥1.04 Billion | -3.53% |
| 2022 | CN¥1.07 Billion | -19.85% |
| 2021 | CN¥1.34 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $881.33 Million USD |
| MoneyControl | $881.33 Million USD |
| MarketWatch | $881.33 Million USD |
| marketcap.company | $881.33 Million USD |
| Reuters | $881.33 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.
Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. operates as a pharmaceutical technology research and development and services company in China. The company primarily provides drug research and development services; and the transformation of research and development technology results for various pharmaceutical, as well as pharmaceutical research and development investment companies. Its business cove… Read more